Ascletis Pharma announced positive topline results from a U.S. Phase II 24-week study of subcutaneous depot formulation A1 of ASC30, a small molecule GLP-1R agonist, achieving 6.3% placebo-adjusted weight loss at Week 12 and 7.5% at Week 16 after three monthly doses without weekly lead-in12.
Weight loss was maintained at 6.4% at Week 20 and 5.8% at Week 24 (four months post-final dose), supporting potential once-monthly treatment and once-quarterly maintenance dosing for obesity12.
ASC30 A1 showed a safety profile consistent with the GLP-1 class, with all adverse events mild to moderate and no discontinuations due to AEs2.
One formulation (A2) failed to achieve therapeutic exposures; study involved 65 obese or overweight participants with comorbidities12.
Search results lack details on Mineralys Therapeutics' Phase 2 apnea trial missing its primary endpoint; no specific data available in provided sources.
Sources:
1. https://www.fiercebiotech.com/biotech/ascletis-posts-phase-2-obesity-data-touts-potential-quarterly-glp-1-dosing
2. https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-ii-24-week-study-for-its-ultra-long-acting-subcutaneous-depot-formulations-of-small-molecule-glp-1r-agonist-asc30-for-obesity-302709245.html